Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of primary paclitaxel plus gemcitabine in patients with stage II and III breast cancer

Next Previous
Trial Profile

Phase II study of primary paclitaxel plus gemcitabine in patients with stage II and III breast cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 23 Jun 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 20 Jun 2011 Actual initiation date (Sep 2005) added as reported by ClinicalTrials.gov.
  • 20 Jun 2011 Planned end date (Aug 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top